Artículo
Compassionate use of ruxolitinib in acute and chronic graft versus host disease refractory both to corticosteroids and extracorporeal photopheresis
Autor/es | Maldonado, Mauricio Sarmiento
Ramírez Villanueva, Pablo Bertín Cortes-Monroy, Pablo Jara Arias, Veronica Soto Donoso, Katherine Uribe Gonzalez, Pablo Ocqueteau Tachini, Mauricio Pérez Simón, José Antonio |
Departamento | Universidad de Sevilla. Departamento de Medicina Instituto de Biomedicina de Sevilla (IBIS) |
Fecha de publicación | 2017 |
Fecha de depósito | 2024-05-06 |
Publicado en |
|
Resumen | Background: Ruxolitinib is a potent inhibitor of JAK1/2 with proven efcacy in myelofbrosis. In recent years, research
in graft versus host disease (GVHD) has revealed the role of activation of JAK pathways in alloreactive ... Background: Ruxolitinib is a potent inhibitor of JAK1/2 with proven efcacy in myelofbrosis. In recent years, research in graft versus host disease (GVHD) has revealed the role of activation of JAK pathways in alloreactive lymphocytes. Some reports have shown signifcant responses in refractory GVHD patients. Cases presentation: In this report we present our experience in 8 patients with acute or chronic GVHD with refrac‑ toriness to steroids and extracorporeal photopheresis treated with ruxolitinib. Three patients had acute GVHD (1 pulmonary, 2 cutaneous, 1 multi-systemic) and 5 had chronic GVHD (3 cutaneous); 85% obtained an overall response and 50% a complete response with a tolerable toxicity profle. Conclusions: In our series, Ruxolitinib was very active as a rescue therapy for patients with acute or chronic GVHD refractory to standard treatment |
Cita | Maldonado, M.S., Ramírez Villanueva, P., Bertín Cortes-Monroy, P., Jara Arias, V., Soto Donoso, K., Uribe Gonzalez, P.,...,Pérez Simón, J.A. (2017). Compassionate use of ruxolitinib in acute and chronic graft versus host disease refractory both to corticosteroids and extracorporeal photopheresis. Experimental Hematology & Oncology, 6 (1), 32. https://doi.org/10.1186/s40164-017-0092-3. |
Ficheros | Tamaño | Formato | Ver | Descripción |
---|---|---|---|---|
Compassionate use...pdf | 1.323Mb | [PDF] | Ver/ | |